Switch to:
Also traded in: Germany, India, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.29
RDY's Cash-to-Debt is ranked lower than
73% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. RDY: 0.29 )
Ranked among companies with meaningful Cash-to-Debt only.
RDY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.68 Max: 42.27
Current: 0.29
0.1
42.27
Equity-to-Asset 0.57
RDY's Equity-to-Asset is ranked lower than
61% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. RDY: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
RDY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.56 Max: 0.82
Current: 0.57
0.31
0.82
Debt-to-Equity 0.41
RDY's Debt-to-Equity is ranked lower than
58% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. RDY: 0.41 )
Ranked among companies with meaningful Debt-to-Equity only.
RDY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.38 Max: 1.39
Current: 0.41
0.01
1.39
Interest Coverage 17.96
RDY's Interest Coverage is ranked lower than
59% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.31 vs. RDY: 17.96 )
Ranked among companies with meaningful Interest Coverage only.
RDY' s Interest Coverage Range Over the Past 10 Years
Min: 2.17  Med: 20.74 Max: 35.86
Current: 17.96
2.17
35.86
Piotroski F-Score: 5
Altman Z-Score: 4.07
Beneish M-Score: -2.17
WACC vs ROIC
-1.57%
7.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 9.01
RDY's Operating Margin % is ranked higher than
74% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. RDY: 9.01 )
Ranked among companies with meaningful Operating Margin % only.
RDY' s Operating Margin % Range Over the Past 10 Years
Min: -4.08  Med: 17.33 Max: 19.7
Current: 9.01
-4.08
19.7
Net Margin % 8.03
RDY's Net Margin % is ranked higher than
60% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. RDY: 8.03 )
Ranked among companies with meaningful Net Margin % only.
RDY' s Net Margin % Range Over the Past 10 Years
Min: -7.44  Med: 13.69 Max: 16.28
Current: 8.03
-7.44
16.28
ROE % 9.51
RDY's ROE % is ranked higher than
62% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. RDY: 9.51 )
Ranked among companies with meaningful ROE % only.
RDY' s ROE % Range Over the Past 10 Years
Min: -11.56  Med: 19.33 Max: 27.58
Current: 9.51
-11.56
27.58
ROA % 5.26
RDY's ROA % is ranked higher than
60% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. RDY: 5.26 )
Ranked among companies with meaningful ROA % only.
RDY' s ROA % Range Over the Past 10 Years
Min: -6.1  Med: 11.05 Max: 13.77
Current: 5.26
-6.1
13.77
ROC (Joel Greenblatt) % 14.80
RDY's ROC (Joel Greenblatt) % is ranked higher than
55% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. RDY: 14.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RDY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7.46  Med: 30.48 Max: 36.82
Current: 14.8
-7.46
36.82
3-Year Revenue Growth Rate 2.90
RDY's 3-Year Revenue Growth Rate is ranked lower than
58% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. RDY: 2.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RDY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.4  Med: 14.5 Max: 46.1
Current: 2.9
0.4
46.1
3-Year EBITDA Growth Rate -8.10
RDY's 3-Year EBITDA Growth Rate is ranked lower than
79% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. RDY: -8.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RDY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -37  Med: 12.5 Max: 154.4
Current: -8.1
-37
154.4
3-Year EPS without NRI Growth Rate -17.00
RDY's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. RDY: -17.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RDY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65  Med: 20.2 Max: 154.7
Current: -17
-65
154.7
GuruFocus has detected 5 Warning Signs with Dr Reddy's Laboratories Ltd $RDY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RDY's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

RDY Guru Trades in Q3 2016

Ken Fisher 5,696,909 sh (+8.99%)
Jim Simons Sold Out
Sarah Ketterer 191,543 sh (-34.98%)
Jeremy Grantham 50,200 sh (-37.41%)
» More
Q4 2016

RDY Guru Trades in Q4 2016

Sarah Ketterer 217,943 sh (+13.78%)
Ken Fisher 5,621,898 sh (-1.32%)
Jeremy Grantham 35,000 sh (-30.28%)
» More
Q1 2017

RDY Guru Trades in Q1 2017

Jim Simons 110,223 sh (New)
Jeremy Grantham Sold Out
Ken Fisher 5,552,562 sh (-1.23%)
Sarah Ketterer 197,886 sh (-9.20%)
» More
Q2 2017

RDY Guru Trades in Q2 2017

Jeremy Grantham 6,700 sh (New)
Jim Simons 284,700 sh (+158.29%)
Ken Fisher 5,599,434 sh (+0.84%)
Sarah Ketterer 188,543 sh (-4.72%)
» More
» Details

Insider Trades

Latest Guru Trades with RDY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Add 0.84%$37.28 - $42.44 $ 37.66-7%5,599,434
Ken Fisher 2017-03-31 Reduce -1.23%0.01%$39.05 - $46.7 $ 37.66-13%5,552,562
Ken Fisher 2016-12-31 Reduce -1.32%0.01%$44.12 - $49.67 $ 37.66-19%5,621,898
Ken Fisher 2016-09-30 Add 8.99%0.04%$43.61 - $54.45 $ 37.66-21%5,696,909
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NSE:AUROPHARMA, BOM:500257, BOM:532321, NSE:DIVISLAB, NSE:ALKEM, BOM:532296, BOM:532872, BOM:533573, NSE:STAR, BOM:540596, BOM:524494, BOM:540222, BOM:530549, BOM:530239, BOM:500126, BOM:532612, BOM:506235, BOM:524558, BOM:590006, NSE:RPGLIFE » details
Traded in other countries:RDDA.Germany, 500124.India, RDY N.Mexico,
Headquarter Location:India
Dr Reddy's Laboratories Ltd is associated with the healthcare sector. Its core business includes the manufacturing of pharmaceutical products.

With headquarters in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceuticals. The firm operates in three divisions: global generics, proprietary products, and active chemical ingredients. The global generics and pharmaceutical services and active ingredients segments make up most of the company's revenue at about 80% and 17%, respectively. About 85% of Dr. Reddy's sales are based outside of India, with approximately 48% from North America and 12% from Europe.

Top Ranked Articles about Dr Reddy's Laboratories Ltd

DR. REDDY'S SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - (RDY)
DR. REDDY ALERT: Rosen Law Firm Reminds Dr. Reddy’s Laboratories Ltd. Investors of Important Deadline in First Filed Class Action – RDY
DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm
DR. REDDY'S SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - (RDY)
The Klein Law Firm Announces a Class Action Filed on Behalf of Dr. Reddy’s Laboratories Ltd. Shareholders and a Lead Plaintiff Deadline of October 24, 2017 (RDY)
DR. REDDY’S SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dr. Reddy’s Laboratories Ltd. – (RDY)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Dr. Reddy’s Laboratories Ltd. – RDY
RDY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Dr. Reddy’s Laboratories Ltd. and a Lead Plaintiff Deadline of October 24, 2017
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Encourages Investors with Losses to Contact the Firm
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Encourages Investors with Losses to Contact the Firm

Ratios

vs
industry
vs
history
PE Ratio 36.63
RDY's PE Ratio is ranked lower than
64% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.93 vs. RDY: 36.63 )
Ranked among companies with meaningful PE Ratio only.
RDY' s PE Ratio Range Over the Past 10 Years
Min: 10.61  Med: 23.46 Max: 361.99
Current: 36.63
10.61
361.99
Forward PE Ratio 22.12
RDY's Forward PE Ratio is ranked lower than
55% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.90 vs. RDY: 22.12 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 36.63
RDY's PE Ratio without NRI is ranked lower than
64% of the 554 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.21 vs. RDY: 36.63 )
Ranked among companies with meaningful PE Ratio without NRI only.
RDY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.61  Med: 23.46 Max: 361.99
Current: 36.63
10.61
361.99
PB Ratio 3.36
RDY's PB Ratio is ranked lower than
62% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. RDY: 3.36 )
Ranked among companies with meaningful PB Ratio only.
RDY' s PB Ratio Range Over the Past 10 Years
Min: 1.27  Med: 4.62 Max: 6.72
Current: 3.36
1.27
6.72
PS Ratio 2.93
RDY's PS Ratio is ranked lower than
51% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. RDY: 2.93 )
Ranked among companies with meaningful PS Ratio only.
RDY' s PS Ratio Range Over the Past 10 Years
Min: 0.94  Med: 3.13 Max: 4.84
Current: 2.93
0.94
4.84
Price-to-Operating-Cash-Flow 28.77
RDY's Price-to-Operating-Cash-Flow is ranked lower than
52% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.02 vs. RDY: 28.77 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RDY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.8  Med: 20.71 Max: 41.05
Current: 28.77
6.8
41.05
EV-to-EBIT 30.80
RDY's EV-to-EBIT is ranked lower than
69% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. RDY: 30.80 )
Ranked among companies with meaningful EV-to-EBIT only.
RDY' s EV-to-EBIT Range Over the Past 10 Years
Min: -531.5  Med: 18.7 Max: 276.7
Current: 30.8
-531.5
276.7
EV-to-EBITDA 17.23
RDY's EV-to-EBITDA is ranked higher than
50% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. RDY: 17.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
RDY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.5  Med: 14.75 Max: 75.1
Current: 17.23
-43.5
75.1
EV-to-Revenue 3.12
RDY's EV-to-Revenue is ranked lower than
51% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. RDY: 3.12 )
Ranked among companies with meaningful EV-to-Revenue only.
RDY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1  Med: 3.3 Max: 4.9
Current: 3.12
1.1
4.9
PEG Ratio 8.02
RDY's PEG Ratio is ranked lower than
87% of the 313 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. RDY: 8.02 )
Ranked among companies with meaningful PEG Ratio only.
RDY' s PEG Ratio Range Over the Past 10 Years
Min: 0.3  Med: 1 Max: 16.94
Current: 8.02
0.3
16.94
Shiller PE Ratio 35.31
RDY's Shiller PE Ratio is ranked higher than
54% of the 198 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.37 vs. RDY: 35.31 )
Ranked among companies with meaningful Shiller PE Ratio only.
RDY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 27.85  Med: 58.02 Max: 68.87
Current: 35.31
27.85
68.87
Current Ratio 1.53
RDY's Current Ratio is ranked lower than
83% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. RDY: 1.53 )
Ranked among companies with meaningful Current Ratio only.
RDY' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.78 Max: 5.29
Current: 1.53
1.04
5.29
Quick Ratio 1.10
RDY's Quick Ratio is ranked lower than
83% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. RDY: 1.10 )
Ranked among companies with meaningful Quick Ratio only.
RDY' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.35 Max: 4.3
Current: 1.1
0.68
4.3
Days Inventory 162.36
RDY's Days Inventory is ranked lower than
79% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. RDY: 162.36 )
Ranked among companies with meaningful Days Inventory only.
RDY' s Days Inventory Range Over the Past 10 Years
Min: 134.21  Med: 145.78 Max: 162.36
Current: 162.36
134.21
162.36
Days Sales Outstanding 115.09
RDY's Days Sales Outstanding is ranked lower than
67% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. RDY: 115.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
RDY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.8  Med: 98.57 Max: 127.4
Current: 115.09
49.8
127.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.83
RDY's Dividend Yield % is ranked lower than
77% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. RDY: 0.83 )
Ranked among companies with meaningful Dividend Yield % only.
RDY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.31  Med: 0.64 Max: 1.01
Current: 0.83
0.31
1.01
Dividend Payout Ratio 0.29
RDY's Dividend Payout Ratio is ranked higher than
60% of the 406 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.33 vs. RDY: 0.29 )
Ranked among companies with meaningful Dividend Payout Ratio only.
RDY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.16 Max: 0.99
Current: 0.29
0.12
0.99
3-Year Dividend Growth Rate 10.10
RDY's 3-Year Dividend Growth Rate is ranked higher than
60% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.90 vs. RDY: 10.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
RDY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -10.6  Med: 15.75 Max: 171.4
Current: 10.1
-10.6
171.4
Forward Dividend Yield % 0.83
RDY's Forward Dividend Yield % is ranked lower than
79% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. RDY: 0.83 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.51
RDY's 5-Year Yield-on-Cost % is ranked lower than
66% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. RDY: 1.51 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
RDY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.56  Med: 1.16 Max: 1.84
Current: 1.51
0.56
1.84
3-Year Average Share Buyback Ratio 0.90
RDY's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. RDY: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RDY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.6  Med: -0.2 Max: 0.9
Current: 0.9
-6.6
0.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 81.87
RDY's Price-to-Net-Current-Asset-Value is ranked lower than
96% of the 512 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. RDY: 81.87 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RDY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.53  Med: 16.7 Max: 230.86
Current: 81.87
5.53
230.86
Price-to-Tangible-Book 5.55
RDY's Price-to-Tangible-Book is ranked lower than
71% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.51 vs. RDY: 5.55 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RDY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.07  Med: 6.26 Max: 83.42
Current: 5.55
3.07
83.42
Price-to-Intrinsic-Value-Projected-FCF 2.60
RDY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
52% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. RDY: 2.60 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RDY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.47  Med: 3.01 Max: 4.58
Current: 2.6
1.47
4.58
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.42
RDY's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
88% of the 83 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. RDY: 3.42 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
RDY' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 1.68  Med: 2.35 Max: 4.94
Current: 3.42
1.68
4.94
Price-to-Median-PS-Value 0.94
RDY's Price-to-Median-PS-Value is ranked higher than
60% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. RDY: 0.94 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RDY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 1.03 Max: 1.78
Current: 0.94
0.38
1.78
Price-to-Graham-Number 3.01
RDY's Price-to-Graham-Number is ranked lower than
70% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. RDY: 3.01 )
Ranked among companies with meaningful Price-to-Graham-Number only.
RDY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.67  Med: 2.69 Max: 11.05
Current: 3.01
1.67
11.05
Earnings Yield (Greenblatt) % 3.24
RDY's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. RDY: 3.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RDY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.8  Med: 5 Max: 11.6
Current: 3.24
-4.8
11.6
Forward Rate of Return (Yacktman) % 3.65
RDY's Forward Rate of Return (Yacktman) % is ranked lower than
57% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. RDY: 3.65 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RDY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.4  Med: 3.4 Max: 48.4
Current: 3.65
-9.4
48.4

More Statistics

Revenue (TTM) (Mil) $2,138.77
EPS (TTM) $ 1.03
Short Percentage of Float0.00%
52-Week Range $29.83 - 50.10
Shares Outstanding (Mil)165.80 (ADR)

Analyst Estimate

Mar18 Mar19
Revenue (Mil $) 2,516 2,767
EPS ($) 1.73 2.24
EPS without NRI ($) 1.73 2.24
EPS Growth Rate
(Future 3Y To 5Y Estimate)
25.82%
Dividends per Share ($) 0.26 0.31
» More Articles for RDY

Headlines

Articles On GuruFocus.com
DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding Sep 20 2017 
DR. REDDY'S SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS I Sep 15 2017 
The Klein Law Firm Announces a Class Action Filed on Behalf of Dr. Reddy’s Laboratories Ltd. Sh Sep 12 2017 
DR. REDDY’S SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 Sep 08 2017 
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Dr. Reddyâ Sep 08 2017 
RDY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Sep 08 2017 
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Redd Sep 07 2017 
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddyâ Sep 07 2017 
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Dr. Sep 06 2017 
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Dr. R Sep 05 2017 

More From Other Websites
DR. REDDY'S SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of... Sep 22 2017
DR. REDDY ALERT: Rosen Law Firm Reminds Dr. Reddy’s Laboratories Ltd. Investors of Important... Sep 22 2017
Dr. Reddy's Laboratories (RDY) Surges: Stock Moves 5.7% Higher Sep 22 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr.... Sep 20 2017
DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding... Sep 20 2017
RDY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action... Sep 20 2017
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr.... Sep 19 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Dr. Reddy's Laboratories Ltd. of... Sep 19 2017
Scott+Scott, Attorneys at Law, LLP Reminds Investors of October 24th Lead Plaintiff Deadline in... Sep 19 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr.... Sep 19 2017
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Dr.... Sep 18 2017
EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy’s... Sep 15 2017
DR. REDDY'S SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS... Sep 15 2017
RDY EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Dr.... Sep 15 2017
EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's... Sep 14 2017
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddy’s Laboratories Ltd. of... Sep 14 2017
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's... Sep 13 2017
The Klein Law Firm Announces Commencement of a Class Action Filed on Behalf of Dr. Reddy’s... Sep 13 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Sep 13 2017
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's... Sep 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}